Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $5.3 million.

  • Immuneering's Cash from Financing Activities fell 623.14% to -$40,988 in Q4 2024 from the same period last year, while for Dec 2024 it was $5.3 million, marking a year-over-year decrease of 81.33%. This contributed to the annual value of $5.3 million for FY2024, which is 81.35% down from last year.
  • As of FY2024, Immuneering's Cash from Financing Activities stood at $5.3 million, which was down 81.35% from $28.4 million recorded in FY2023.
  • Immuneering's Cash from Financing Activities' 5-year high stood at $144.3 million during FY2021, with a 5-year trough of $19,004 in FY2022.
  • Its 3-year average for Cash from Financing Activities is $11.3 million, with a median of $5.3 million in 2024.
  • In the last 5 years, Immuneering's Cash from Financing Activities slumped by 99.99% in 2022 and then surged by 149,558.35% in 2023.
  • Yearly analysis of 5 years shows Immuneering's Cash from Financing Activities stood at $38.0 million in 2020, then skyrocketed by 279.82% to $144.3 million in 2021, then tumbled by 99.99% to $19,004 in 2022, then skyrocketed by 149,558.35% to $28.4 million in 2023, then slumped by 81.35% to $5.3 million in 2024.